RxDoctor Payments Data

Merrill Stewart, MD

Cardiovascular Disease · New Orleans, LANPI 1679830111

Payments from drug & device makers

$2,029in general payments, 2019–2025

Across 87 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$430
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$265
  • Kestra Medical Technology Services, Inc.$228
  • AstraZeneca$225
  • Novo Nordisk$181
  • Amgen$162
  • plus $539 from 10 others

What the payments were for

  • Food & beverage$2,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,029 in reported general payments places this provider in the 40th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$62,058
Medicare patients
645
Services billed
1,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$160,238
EntrestoSacubitril/Valsartan147$118,564
Repatha SureclickEvolocumab137$91,544
XareltoRivaroxaban28$33,483
Repatha SyringeEvolocumab28$19,490
WegovySemaglutide15$18,932
JardianceEmpagliflozin11$11,055
NexlizetBempedoic Acid/Ezetimibe12$7,223
Metoprolol Succinate220$2,305
Atorvastatin Calcium192$2,249
Rosuvastatin Calcium224$2,122
Carvedilol128$1,255
Valsartan60$1,054
Ezetimibe51$1,051
Flecainide Acetate31$832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$160,238195 claims
NovartisEntresto$131$118,564147 claims
Johnson & JohnsonXarelto$430$33,48328 claims
Novo NordiskWegovy$181$18,93215 claims
Boehringer IngelheimJardiance$28$11,05511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →